MRD指导的泽布替尼、维奈克拉与奥妥珠单抗治疗复发CLL:CLL2-BZAG试验主要终点分析
中位观察21.5个月,6个月三联后全部缓解,21例(52.5%;95%CI 36.1-68.5)外周血uMRD,最佳uMRD率85%,18个月PFS率96%、OS率96.8%。
要点
- 6个月三联后全部缓解,外周血uMRD率52.5%(95%CI 36.1-68.5),最佳uMRD率85%。
- 18个月估计PFS率96%、OS率96.8%,截至报告无患者需后续治疗。
- 最常见不良事件为COVID-19(26例),2例发生致死性不良事件(COVID-19及继发真菌性肺炎)。
核心结论
- MRD指导的泽布替尼、维奈克拉与奥妥珠单抗三联方案在既往接受过BTK抑制剂/维奈克拉的复发CLL人群中诱导深度缓解。
研究设计与样本
- 2期CLL2-BZAG试验,评估可选苯达莫司汀减瘤后MRD指导的泽布替尼、维奈克拉与奥妥珠单抗联合治疗复发/难治CLL。
- 患者既往中位治疗线数1线(范围1-5);18例(45%)已接受BTK抑制剂,7例(17.5%)维奈克拉,其中5例(12.5%)两者均用过。
- 15例(37.5%)有TP53突变/缺失,31例(77.5%)免疫球蛋白重链可变区基因未突变。
- 中位观察时间21.5个月(范围8.0-35.3)。
主要发现
- 最常见不良事件为COVID-19(26例)、腹泻(15例)、输注相关反应(15例)、血小板减少(14例)、恶心(12例)、疲乏(12例)和中性粒细胞减少(12例)。
- 2例发生致死性不良事件(COVID-19,以及COVID-19继发真菌性肺炎)。
- 三联治疗6个月后全部患者缓解,21例(52.5%;95%CI 36.1-68.5)外周血uMRD。
- 许多患者缓解随时间加深,最佳uMRD率为85%。
- 18个月估计无进展生存率96%、总生存率96.8%;截至报告无患者需要后续治疗。
关键数值与推荐
- 6个月三联后外周血uMRD率52.5%(95%CI 36.1-68.5)。
- 最佳uMRD率85%。
- 18个月估计PFS率96%、OS率96.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax, and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). In total, 42 patients were enrolled and 2 patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of 1 prior therapy (range, 1-5); 18 patients (45%) had already received a Bruton tyrosine kinase (BTK) inhibitor (BTKi); 7 patients (17.5%) venetoclax; and, of these, 5 (12.5%) had received both. Fifteen patients (37.5%) had a TP53 mutation/deletion, and 31 (77.5%) had unmutated immunoglobulin heavy chain variable region gene. With a median observation time of 21.5 months (range, 8.0-35.3) the most common adverse events were COVID-19 (n = 26 patients), diarrhea (n = 15), infusion-related reactions (n = 15), thrombocytopenia (n = 14), nausea (n = 12), fatigue (n = 12), and neutropenia (n = 12). Two patients had fatal adverse events (COVID-19, and fungal pneumonia secondary to COVID-19). After 6 months of the triple combination, all patients responded, and 21 (52.5%; 95% confidence interval, 36.1-68.5) showed undetectable MRD (uMRD) in the peripheral blood. In many patients, remissions deepened over time, with a best uMRD rate of 85%. The estimated progression-free and overall survival rates at 18 months were 96% and 96.8%, respectively. No patient has yet required a subsequent treatment. In summary, the MRD-guided triple combination of zanubrutinib, venetoclax, and obinutuzumab induced deep remissions in a relapsed CLL population enriched for patients previously treated with a BTKi/venetoclax. This trial was registered at www.clinicaltrials.gov as #NCT04515238.
引用
- Fürstenau M, Robrecht S, Schneider C, et al. MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial. Blood. 2025. PMID: 39883943. doi:10.1182/blood.2024026685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。